Search results for " screening"

showing 10 items of 898 documents

Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability

2003

Abstract Background and methods : Lipoprotein(a) [Lp(a)] levels represent an independent risk factor for cardio- and cerebrovascular diseases. Since lipoprotein(a) levels show a wide variability even in subjects with similar apolipoprotein(a) isoforms, we investigated the contribution of apolipoprotein(a) heterozygosity to lipoprotein(a) variance. Lipoprotein(a) levels, apolipoprotein(a) isoforms identification and expression, and the correlation with other lipo-apolipoprotein parameters have been investigated in 628 subjects >18 years of age. Results : In our study, 246 subjects were found heterozygous for apolipoprotein(a) isoforms. Lipoprotein(a) levels were higher in females. About 40% …

Gene isoformAdultMalemedicine.medical_specialtyHeterozygoteApolipoprotein BClinical BiochemistryWestern blotApoprotein(a)BiochemistryProtein expressionLoss of heterozygosityWestern blotInternal medicinemedicineHumansProtein IsoformsAgedApolipoprotein(a) phenotypingmedicine.diagnostic_testbiologyMedical screeningBiochemistry (medical)General MedicineLipoprotein(a)Middle AgedEndocrinologyApolipoproteinsbiology.proteinProtein expressionlipids (amino acids peptides and proteins)FemaleLipoproteinLipoprotein(a)
researchProduct

Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-based Pharmacophore Modeling/Docking Approach

2020

To date, SARS-CoV-2 infectious disease, named COVID-19 by the World Health Organization (WHO) in February 2020, has caused millions of infections and hundreds of thousands of deaths. Despite the scientific community efforts, there are currently no approved therapies for treating this coronavirus infection. The process of new drug development is expensive and time-consuming, so that drug repurposing may be the ideal solution to fight the pandemic. In this paper, we selected the proteins encoded by SARS-CoV-2 and using homology modeling we identified the high-quality model of proteins. A structure-based pharmacophore modeling study was performed to identify the pharmacophore features for each…

General Computer ScienceComputer scienceComputational biologylcsh:QA75.5-76.95Theoretical Computer Science03 medical and health sciences0302 clinical medicineHomology modelingMM-GBSA030304 developmental biology0303 health sciencesVirtual screeningpharmacophoreSARS-CoV-2Applied MathematicsCOVID-19computational chemistryCOVID-19 SARS-CoV-2 computational chemistry structure-based pharmacophore docking MM-GBSADrug repositioningstructure-basedDrug developmentInfectious disease (medical specialty)Docking (molecular)030220 oncology & carcinogenesisModeling and Simulationdockinglcsh:Electronic computers. Computer sciencePharmacophoreDrugBankComputation
researchProduct

Identification of a genetic contamination in a commercial mouse strain using two panels of polymorphic markers

2007

Rapid detection of genetic contamination is critical in mouse studies involving inbred strains. During a Quantitative Trait Locus (QTL) study using simple sequence length polymorphism (SSLP) markers, we noticed heterozygosity at some loci of a commercially available inbred C57BL/6N mouse strain, suggesting a contamination by another mouse strain. A panel of 100 single-nucleotide polymorphism (SNP) markers was used to confirm and specify the genetic contamination suspected. Retrospective analyses demonstrated that the contamination took place as early as autumn 2003 and has persisted ever since at a fairly constant level. Contaminating alleles most probably originated from a DBA strain. Our…

Genetic MarkersGenotypeMice Inbred StrainsBiologyQuantitative trait locusMice03 medical and health sciences0302 clinical medicineInbred strainGenotypeAnimalsGenetic TestingAlleleSimple sequence length polymorphism030304 developmental biologyGeneticsMice Inbred BALB C0303 health sciencesPolymorphism GeneticBase SequenceGeneral VeterinaryGenetic Carrier ScreeningStrain (biology)Mice Inbred C57BLGenetic marker030220 oncology & carcinogenesisAnimal Science and ZoologyGenetic monitoringLaboratory Animals
researchProduct

Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system

2003

Many hereditary factors have been implicated in the development of arterial and/or venous thromboembolic diseases. A number of these risk factors can be identified by the amplification refractory mutation system (ARMS). However, the underlying technical conditions for performing ARMS are highly variable, and depend on which risk factors are being analyzed. We have now developed a novel ARMS-based system to simultaneously screen for multiple hypercoagulability factors under identical PCR conditions. This can greatly simplify the process of screening for hereditary hypercoagulability.

GeneticsBase SequenceGenetic Carrier ScreeningHomozygoteGenetic Carrier ScreeningSingle-strand conformation polymorphismBlood ProteinsHematologyBlood Coagulation DisordersBiologymedicine.diseaseThrombophiliaBioinformaticsPolymerase Chain ReactionThrombosisBlood Coagulation FactorsRefractoryMutation (genetic algorithm)medicineCoagulopathyHumansMass ScreeningRisk factorDNA PrimersThrombosis Research
researchProduct

Detection of mammalian carcinogens with an immunological DNA synthesis-inhibition test.

1992

There is a close relationship between genotoxicity, mutagenicity and carcinogenicity. But the controversy of which short-term test system best recognizes human carcinogens is still going on. Currently, the Salmonella gene mutation assay ('Ames test') is the most widely used test for the screening of mutagens. However, many in vitro tests hold unsatisfactory validity data, presumably because of the inability of present short-term tests to detect non-genotoxic carcinogens, which are increasingly being brought into focus in the discussions of genesis of cancer. One principle often neglected in this context is the property of genotoxic agents to inhibit replicative DNA synthesis in (proliferati…

GeneticsDNA ReplicationCancer ResearchDNA synthesisDNA damageCarcinogenicity TestsContext (language use)General MedicineGene mutationBiologymedicine.disease_causeAmes testImmunoenzyme TechniquesCarcinogen ScreeningmedicineCarcinogensHumansFalse Positive ReactionsCarcinogenGenotoxicityDNA DamageHeLa CellsCarcinogenesis
researchProduct

The time to prevent mendelian genetic diseases from donated or own gametes has come

2015

GeneticsOocyte DonationGenetic Carrier ScreeningGenetic Diseases InbornInfant NewbornObstetrics and GynecologyGenetic CounselingBiologysymbols.namesakeGerm CellsReproductive MedicinePregnancyMendelian inheritancesymbolsHumansFemaleFertility and Sterility
researchProduct

Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease

2005

Fabry disease (FD) is an X-chromosomal disorder caused by mutations in the GLA gene encoding the lysosomal enzyme alpha-galactosidase A. We performed mutation screening on a cohort of 121 patients including 84 male and 37 female index cases and identified a total of 90 different mutations, 34 of which are reported for the first time here. Both point mutations (74.4%) and 'short length' rearrangements (25.6%) were found, including missense (54.4%), nonsense (14.4%), and splice site point mutations (5.6%), deletions (17.8%) or insertions/duplications (5.6%) of a few nucleotides, and complex rearrangements including larger deletions (2.2%). GLA mutations were identified in 82 (97.6%) of the 84…

GeneticsPoint mutationmedia_common.quotation_subjectNonsenseBiologymedicine.diseaseFabry diseaseGla geneRNA splicingGeneticsmedicineMutation screeningMissense mutationPeptide sequenceGenetics (clinical)media_commonHuman Mutation
researchProduct

PATHOGENIC VARIANTS WITHIN ACMG SECONDARY FINDINGS GENES IN 24,591 HEALTHY INDIVIDUALS USING CLINICAL EXOME SEQUENCING FOR CARRIER SCREENING

2020

GeneticsReproductive MedicineHealthy individualsObstetrics and GynecologyBiologyCarrier screeningGeneExome sequencingFertility and Sterility
researchProduct

A novel approach to CFTR mutation testing by pyrosequencing-based assay panels adapted to ethnicities.

2009

Abstract Background: Cystic fibrosis (CF) is a common autosomal recessive genetic disorder caused by a variety of sequence alterations in the CFTR gene [cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)]. Because the relative prevalence of mutations strongly depends on the ethnic background, first-level testing of CF as defined by recent consensus recommendations ought to be adaptable to the ethnicity of patients. Methods: We therefore developed and implemented a diagnostic approach to first-level testing for CF based on published mutation frequencies and Pyrosequencing (PSQ) technology that we complemented with standard procedures of mutation…

Geneticsmedicine.diagnostic_testbiologyBase SequenceCystic FibrosisGenetic Carrier ScreeningBiochemistry (medical)Clinical BiochemistryGenetic disorderCystic Fibrosis Transmembrane Conductance RegulatorSequence Analysis DNAmedicine.diseaseCystic fibrosisPolymerase Chain ReactionCystic fibrosis transmembrane conductance regulatorCftr mutationCase-Control StudiesMutation (genetic algorithm)Mutationmedicinebiology.proteinPyrosequencingHumansGenotypingSweat testClinical chemistry
researchProduct

Screening for microdeletions of the X-chromosome in non-specific mental retardation

2003

Geneticsmedicine.diagnostic_testbusiness.industryMedical screeningmedicine.diseaselaw.inventionDevelopmental disorderNon specificlawGene duplicationIntellectual disabilityGeneticsMedicinebusinessGenetics (clinical)X chromosomePolymerase chain reactionGenetic testingAmerican Journal of Medical Genetics Part A
researchProduct